NCT03441607Unknown2 期
Safety & Efficacy of Micronized Human Amnion Chorion Membrane Biologic (mHACMb) FloGraft (Micronized Human Amnion Chorion Membrane)® in Adults With Pain Due to Osteoarthritis of the Knee
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 320
- 试验地点
- 1
- 主要终点
- Visual Analogue Scale (VAS)
研究概览
简要总结
Safety & Efficacy of FloGraft (Micronized Human Amnion Chorion Membrane)® in Adults With Pain Due to Osteoarthritis of the Knee.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 30 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able to provide written informed consent to participate in the study.
- •Willing and able to participate in all procedures and follow-up evaluations necessary to complete the study.
- •Subject is 30 years or older.
- •Moderate OA pain (rating of at least 20mm on the VAS) assessed at Baseline.
- •Moderate to moderately-severe OA pain in the index knee (rating of at least 1.5 on the WOMAC Index 3.1 5-point Likert Pain Subscale) assessed at Baseline.
- •Must be ambulatory.
- •No analgesia (including acetaminophen [paracetamol]) taken 12 hours prior to an efficacy measure.
排除标准
- •Subject has active infection at the injection site.
- •Subject has rheumatoid arthritis, psoriatic arthritis, or have been diagnosed with any other auto-immune disorders that could be the cause of their knee pain.
- •BMI greater than 40 kg/m
- •Subject has received an intra-articular hyaluronic acid (HA) injection for the treatment of OA of the target knee within 3 months prior to screening.
- •Subject has received an intra-articular amniotic fluid, amniotic membrane or amniotic fluid/membrane combination injection for the treatment of OA of the target knee within 3 months prior to screening.
- •Subject has received a steroid, bone marrow aspirate concentrate (BMAC) or platelet rich plasma (PRP) injection for the treatment of OA of the target knee within 3 months prior to screening.
- •Subject has had major surgery, arthroplasty or arthroscopy in the target knee within 26 weeks of treatment or plans to have surgery in the target knee within 180 days of treatment.
- •Subject is pregnant or plans to become pregnant within 180 days of treatment.
- •Subject has used an investigational drug, device or biologic within 12 weeks prior to treatment.
- •Subject has any significant medical condition that, in the opinion of the Investigator, would interfere with protocol evaluation and participation.
- •Subject is currently taking anticoagulant therapy (excluding Plavix or Aspirin).
- •Diagnosis of gout in the past 6 month.
- •Major injury to the target knee within the 12 months prior to the screening.
- •Severe hip osteoarthritis ipsilateral to the target knee.
- •Any pain that could interfere with the assessment of the target knee pain (e.g. pain in any other part of the lower extremities, pain radiating to the knee).
研究组 & 干预措施
Drug
Active Comparator
Intervention: 40 mg of micronized human amnion chorion membrane biologic (mHACMb); administered 1(x) on second visit; followed by 2 follow-up visits for assessment over a duration of 3 months.
干预措施: mHACMb (Drug)
Placebo
Placebo Comparator
Intervention: 1cc of saline will be administered as a one time injection on visit 2, administered 1(x) on first visit; followed by 2 follow-up visits for assessment over a duration of 3 months.
干预措施: placebo (Other)
结局指标
主要结局
Visual Analogue Scale (VAS)
时间窗: 3 Months
Decreased Pain Level
次要结局
- Western Ontario and McMaster Universities Arthritis Index (WOMAC®) osteoarthritis Index 3.1.(3 Months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Human Amniotic Membrane Grafting and Standard of Care Versus Standard of Care Alone in the Treatment of Venous Leg UlcersVenous Leg UlcerNCT01552447MiMedx Group, Inc.98
Unknown
1 期
Human Amniotic Epithelial Cells for Asherman's SyndromeAsherman's SyndromeNCT03223454The Second Affiliated Hospital of Chongqing Medical University50
尚未招募
不适用
Evaluation of Outcomes With Umbilical Cord Allograft for Musculoskeletal Conditions Musculoskeletal ConditionsOsteoarthritisTendinitisDegenerative ArthritisLigament InjuryNeuropathyPelvic PainSports InjuryDegenerative Disc DiseaseNCT03390920R3 Stem Cell200
终止
不适用
Use of Human Dehydrated Amnion Chorion Allograft in Laryngectomy/PharyngectomyLarynx CancerPharynx CancerPharyngocutaneous FistulaNCT03479463MiMedx Group, Inc.8
终止
不适用
Human Amniotic Membrane On Venous Leg Ulcers In an Elderly PopulationVenous Leg UlcerNCT06544564BioLab Holdings30